Optimizing Care for Lower-Risk Myelodysplastic Syndromes: Translating Evidence to Clinical Practice - Episode 6
Managing Luspatercept Therapy: Dosing, Adverse Effects, and Monitoring
Panelists discuss how they approach luspatercept dosing strategies in clinical practice; manage treatment-related adverse events such as fatigue, hypertension, and diarrhea; and monitor labs for signs of relapse, while also considering real-world dose escalation outcomes and the correlation between peripheral blood and bone marrow biopsy mutations in patients with MDS.
Video Player is loading.
Video content above is prompted by the following:
- What is your dosing strategy for luspatercept in your clinical practice?
- Please comment on Patel K, et al. Real-world luspatercept dose escalation and outcomes. EHA 2024 abstract.
- Please describe some potential treatment-related adverse events associated with luspatercept that you’ve observed in your clinical practice.
- How do you manage fatigue, hypertension, and diarrhea?
- What labs do you monitor and recheck for if you are concerned that this patient is relapsing?
- Resource links: DeZern AE, et al. Correlation between PB and BMBx mutations from national MDS study. ASH 2023 abstract.
Related Content:
